> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Lexicon Diabetes Drug Heads to Panel
- URL: https://www.fdaweb.com/lexicon-diabetes-drug-heads-to-panel/
- Published: 2024-10-01T12:00:00.000Z
- Updated: 2026-09-14T14:42:54.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5157893

*Federal Register* notice: FDA is announcing a 10/31 Endocrinologic and Metabolic Drugs Advisory Committee meeting that will review a Lexicon Pharmaceuticals NDA for sotagliflozin oral tablets. The submission is seeking approval for the drug’s use as an adjunct to insulin therapy for improving glycemic control in adults with Type 1 diabetes mellitus and chronic kidney disease. To view the notice, click [here](https://public-inspection.federalregister.gov/2024-22570.pdf?ref=fdaweb.com).